inclusion criteria: 1. patients of both genders, aged between 18 and 69. 2. patients infected by sars-cov-2 confirmed by pcr. 3. hospitalized patients with symptoms onset 5 days before executing the informed consent. 4. no comorbidities affecting the patient´s prognosis, rendering them high risk patients. 5. documented acceptance to participate by means of the execution of the informed consent. 6. female patients of childbearing age must have a negative pregnancy test and must use adequate contraceptive methods (for example, intrauterine devices, hormonal contraceptives, barrier methods, chastity or tubal ligation) during their participation in the study and for one month after the last medication dose in the case of those receiving ivermectin.

inclusion criteria: 1. patients of both genders, aged between 18 and 69. 2. patients infected by sars-cov-2 confirmed by pcr. 3. hospitalized patients with symptoms onset 5 days before executing the informed consent. 4. no comorbidities affecting the patient´s prognosis, rendering them high risk patients. 5. documented acceptance to participate by means of the execution of the informed consent. 6. female patients of childbearing age must have a negative pregnancy test and must use adequate contraceptive methods (for example, intrauterine devices, hormonal contraceptives, barrier methods, chastity or tubal ligation) during their participation in the study and for one month after the last medication dose in the case of those receiving ivermectin.

inclusion criteria: patients of both genders, aged between 18 and 69. patients infected by sars-cov-2 confirmed by pcr. hospitalized patients with symptoms onset 5 days before executing the informed consent. no comorbidities affecting the patient´s prognosis, rendering them high risk patients. documented acceptance to participate by means of the execution of the informed consent. female patients of childbearing age must have a negative pregnancy test and must use adequate contraceptive methods (for example, intrauterine devices, hormonal contraceptives, barrier methods, chastity or tubal ligation) during their participation in the study and for one month after the last medication dose in the case of those receiving ivermectin.

inclusion criteria: patients of both genders, aged between 18 and 69. patients infected by sars-cov-2 confirmed by pcr. hospitalized patients with symptoms onset 5 days before executing the informed consent. no comorbidities affecting the patient´s prognosis, rendering them high risk patients. documented acceptance to participate by means of the execution of the informed consent. female patients of childbearing age must have a negative pregnancy test and must use adequate contraceptive methods (for example, intrauterine devices, hormonal contraceptives, barrier methods, chastity or tubal ligation) during their participation in the study and for one month after the last medication dose in the case of those receiving ivermectin.

inclusion criteria: 1. patients of both genders, aged between 18 and 69. 2. patients infected by sars-cov-2 confirmed by pcr. 3. hospitalized patients with symptoms onset 5 days before executing the informed consent. 4. no comorbidities affecting the patient´s prognosis, rendering them high risk patients. 5. documented acceptance to participate by means of the execution of the informed consent. 6. female patients of childbearing age must have a negative pregnancy test and must use adequate contraceptive methods (for example, intrauterine devices, hormonal contraceptives, barrier methods, chastity or tubal ligation) during their participation in the study and for one month after the last medication dose in the case of those receiving ivermectin.

inclusion criteria: 1. patients of both genders, aged between 18 and 69. 2. patients infected by sars-cov-2 confirmed by pcr. 3. hospitalized patients with symptoms onset 5 days before executing the informed consent. 4. no comorbidities affecting the patient´s prognosis, rendering them high risk patients. 5. documented acceptance to participate by means of the execution of the informed consent. 6. female patients of childbearing age must have a negative pregnancy test and must use adequate contraceptive methods (for example, intrauterine devices, hormonal contraceptives, barrier methods, chastity or tubal ligation) during their participation in the study and for one month after the last medication dose in the case of those receiving ivermectin.